US FDA Joins Chorus Of Concerns About Results Of GAIN Act
It's too early to say whether program is working, FDA tell Congress; agency has awarded 147 QIDP designations, but none of 12 approved antibacterals have new mechanism of action.
You may also be interested in...
US FDA's center directors chime in on topics such as antimicrobial drug development and public education at the 2019 Reagan-Udall annual meeting.
US FDA and CMS explore reimbursement ideas to strengthen business case for antimicrobial development; new approval pathway likely is only needed in special situations.
The latest drug development news and highlights from our FDA Performance Tracker.